Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Palandri

Showing results (111-120 of 187) with videos related to

Pageof 19
Sort By:
Haematologica|October 8, 2008
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-upFrancesca Palandri, Fausto Castagnetti, Nicoletta Testoni, et al.
Frontiers in Immunology|May 19, 2023
Circulating extracellular particles from severe COVID-19 patients show altered profiling and innate lymphoid cell-modulating abilityDorian Forte, Roberto Maria Pellegrino, Sara Trabanelli, et al.
Blood|October 14, 2009
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemiaGianantonio Rosti, Francesca Palandri, Fausto Castagnetti, et al.
American Journal of Hematology|October 5, 2016
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patientsNicola Polverelli, Massimo Breccia, Giulia Benevolo, et al.
Leukemia|July 12, 2020
Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot studyCarl C Crodel, Kathleen Jentsch-Ullrich, Steffen Koschmieder, et al.
British Journal of Haematology|February 22, 2021
Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective studyElisa Lucchini, Francesca Palandri, Stefano Volpetti, et al.
Thrombosis Research|November 30, 2019
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 yearsFrancesca Palandri, Cristina Santoro, Monica Carpenedo, et al.
British Journal of Haematology|February 5, 2020
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet countsHaifa Kathrin Al-Ali, Martin Griesshammer, Lynda Foltz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2021
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory MyelofibrosisJohn Mascarenhas, Rami S Komrokji, Francesca Palandri, et al.
Blood|March 31, 2011
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysisGiulia Marzocchi, Fausto Castagnetti, Simona Luatti, et al.
Pageof 19

Showing results (111-120 of 187) with videos related to

Sort By:
Pageof 19
Haematologica|October 8, 2008
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-upFrancesca Palandri, Fausto Castagnetti, Nicoletta Testoni, et al.
Frontiers in Immunology|May 19, 2023
Circulating extracellular particles from severe COVID-19 patients show altered profiling and innate lymphoid cell-modulating abilityDorian Forte, Roberto Maria Pellegrino, Sara Trabanelli, et al.
Blood|October 14, 2009
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemiaGianantonio Rosti, Francesca Palandri, Fausto Castagnetti, et al.
American Journal of Hematology|October 5, 2016
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patientsNicola Polverelli, Massimo Breccia, Giulia Benevolo, et al.
Leukemia|July 12, 2020
Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot studyCarl C Crodel, Kathleen Jentsch-Ullrich, Steffen Koschmieder, et al.
British Journal of Haematology|February 22, 2021
Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective studyElisa Lucchini, Francesca Palandri, Stefano Volpetti, et al.
Thrombosis Research|November 30, 2019
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 yearsFrancesca Palandri, Cristina Santoro, Monica Carpenedo, et al.
British Journal of Haematology|February 5, 2020
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet countsHaifa Kathrin Al-Ali, Martin Griesshammer, Lynda Foltz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2021
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory MyelofibrosisJohn Mascarenhas, Rami S Komrokji, Francesca Palandri, et al.
Blood|March 31, 2011
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysisGiulia Marzocchi, Fausto Castagnetti, Simona Luatti, et al.
Pageof 19